Effect of *Bacillus coagulans* Unique IS-2 in Inflammatory Bowel Disease (IBD): A Randomized Controlled Trial

V Deepak Bamola¹, Divya Dubey¹, Projoyita Samanta¹, Saurabh Kedia², Ratna Sudha Madempudi³, Jayanthi Neelamraju³, Vineet Ahuja², Rama Chaudhry^{1*}

¹ Department of Microbiology, ² Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India

³ Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India

*Corresponding author

Abstract

Probiotic intervention is an important approach for the treatment and health restoration in inflammatory bowel disease (IBD). A study was conducted to assess the effect of *Bacillus coagulans* Unique IS-2 in IBD patients. Recruited subjects were given either probiotic *B. coagulans* Unique IS-2 or placebo for 4 weeks as per randomization. Survival of the given probiotic strain in GI, presence of beneficial gut bacteria, serum cytokines, serum serotonin and serum dopamine, symptoms of disease, physical, behavioral and psychological parameters of the subjects were evaluated before and after intervention. In this study *B. coagulans* Unique IS-2 was well tolerated with no severe adverse events in IBD patients and demonstrated good survival in GI tract by significantly high detection in probiotic treated group (p <0.001). Significant enhancement in beneficial *Lactobacilli* was observed in probiotic treated group (p <0.01). Metagenomic analysis also showed an increase in the abundance of bacterial genera *Bacillus*, *Lactobacillus*, *Bifidobacterium*, *Faecalibacterium*, *Bacteroides*, *Megamonas*, *Lachnospira*, *Blautia*, *Alistipes* and decrease in *Sutterella*, *Dialister*, *Roseburia* and *Megasphaera* was observed in the post intervention samples in the treatment group. Increased secretion of cytokine IL-10 and variable decrease in the secretion of IL-6, IL-1 β , TNF- α , IL -17 and IL -23 was observed in in the probiotic treated group. Post intervention change in serum serotonin and serum dopamine was not significant in both the groups. A reduction in the severity of disease symptoms and improvement in the physical, behavioral and psychological parameter was observed in the probiotic treated group. The observed results demonstrated that *B. coagulans* Unique IS-2 with SMT was effective in adult IBD patients. Study was registered with Clinical Trials Registry India (CTRI) - (registration no.- CTRI/2019/11/022087).

Keywords: Inflammatory bowel disease (IBD), Gut Microbiota, Probiotic, *Bacillus coagulans*, Cytokines, Randomized Controlled Trial (RCT)

Introduction

Inflammatory bowel disease (IBD) is a gastrointestinal (GI) disease characterized by chronic inflammation. The incidence of IBD is rising all over the world¹ including Asia². Across the globe India is projected to have one of the highest IBD burden in spite of having lower prevalence as compared to the West^{3,4}. IBD significantly diminishes the quality of life of the affected individuals by disturbing health, daily work, education, and social relationships which cause a considerable impact on health and economy⁵. Etiology and pathogenesis of IBD is multi-factorial and involves genetics, ethnicity, diet, lifestyle, environmental factors, immunity and gut microbiota of the individual^{6,7}. Higher stress level and disturbance in psychology in IBD patients may trigger the inflammation and increases the severity of disease⁸.

The human gut microbiota has demonstrated physiological functions associated with homeostasis, nutrition, immunity and defense of the host. Normally the gut maintains a homeostatic condition but in IBD this homeostasis gets disturbed and leads to intestinal inflammation⁹. Down-regulation of the immune responses may allow the damaged site to heal and reset the normal physiological functions⁷. Alteration in the gut microbiota, referred to as dysbiosis, plays a key role in the pathogenesis of IBD^{10,11}. Dysbiosis may occur in both inflamed and non-inflamed areas in patients¹² and is well recognized sign of IBD¹³. Modification of gut microbiota with probiotic intervention to attenuate inflammatory activity and prevent relapses in IBD are considered as an important approach for treatment and health restoration in IBD^{11,14} by relieving intestinal dysbiosis and GI inflammation¹⁰.

GI disorders modulate the gut function and influence the emotional and cognitive factors including mood, anxiety, pain and negative effects, decision making, restlessness. This change in emotional and cognitive factors may be associated with serum serotonin and dopamine in IBD patients¹⁵. The lowering of serotonin levels can result in mood disorders, such as anxiety or depression and hence consider playing an important role in regulating physical and psychological symptoms¹⁶ and activation of immune response and gut inflammation¹⁵. Dopamine is an important neurotransmitter which affects behavior, psychology, immune functions and GI functions and its unregulated production in IBD is already reported¹⁷. Evaluation of these factors has turn out to be an important factor to monitor the severity of the disease. Gut microbiota and probiotics have demonstrated the effect on behavior, psychology, mood, and cognition^{18,19}.

74 *Bacillus* strains are stable at room temperature and hence gaining a lot of attention. *B.*
75 *coagulans* is a spore-forming, gram-positive, non-pathogenic, facultative anaerobic, lactic
76 acid-producing bacteria and resistant to high temperatures²⁰. *B. coagulans* Qualified
77 Presumption of Safety (QPS) list²¹ and has been reported Generally Recognized as Safe
78 (GRAS) and considered safe by European Union Food Safety Authority (EFSA) and US
79 Food and Drug Administration (FDA). *B coagulans* Unique IS-2 (ATCC PTA-11748,
80 MTCC 5260) is a shelf-stable, resistant to bile acids and acidic conditions of the stomach,
81 clinically established probiotic strain and with proven safety and efficacy in the treatment of
82 constipation, diarrhea^{22–25} bacterial vaginosis²⁶ and irritable bowel syndrome (IBS)²⁷. In this
83 study we assessed the effect of *B coagulans* Unique IS-2 on adults with inflammatory bowel
84 disease (IBD) receiving standard medical treatment (SMT). Survival of the given probiotic *B*
85 *coagulans* Unique IS2 in the gut, presence of beneficial gut bacteria, serum cytokines,
86 serotonin and dopamine, IBD symptoms, physical and psychological parameters were
87 evaluated before and after intervention.

Methodology

- **Study design:** Randomized, double blind, placebo controlled trial. Study was registered with Clinical Trials Registry (CTRI) India (CTRI/2019/11/022087).
- **Site:** Outpatients from a tertiary care hospital.
- **Ethical approval and written informed consent:** Ethical approval for the study was obtained from Institute Ethics Committee of AIIMS, New Delhi, India (Ref – IEC.478/07.10.2016.OP-7). Expected duration of participation, expected benefits, associated risks, and maintenance of confidentiality of records were explained to each participant and a written informed consent was obtained before enrollment in the study.
- **Subject / Selection of patients:** Clinically diagnosed adult patients of ulcerative colitis (UC) with mild to moderate severity between age group (18–60 years) under standard Medical treatment (SMT) patients were included. Simple Clinical Colitis Activity Index (SCCAI) score²⁸ was used to quantify UC disease activity. SCCAI score was calculated by evaluating different disease symptoms including bowel frequency, urgency of defecation, blood in stool, abdominal cramps and general wellbeing of the patients. SMT for the enrolled patient in this study was 5-aminosalicylic acid (5-ASA) - Sulfasalazine (3 grams/ day) or Mesalamine 800 mg orally 3 times a day.
- **Inclusion criteria:** (a) Adult patient clinically diagnosed with Ulcerative Colitis (UC), (b) patients of either sex of the age range from 18-60 year, (d) patient ready to participate in the study and giving written consent, (e) patient visiting to Out Patient Department (OPD) of AIIMS for treatment.
- **Exclusion criteria:** (a) Patient diagnosed with any kind of carcinoma, (b) Patient diagnosed with any other gastrointestinal disease, (c) Patient suffering from Immunodeficiency disorder, (d) Patient is taking any probiotic drug/ or having consumed probiotic in the last one month, (e) patient not taking food through oral route, (f) Patient having undergone any kind of gastrointestinal surgery in the last three month.
- **Enrolment of patients:** After establishing the eligibility on screening, a total of 100 patients were recruited and randomized. Patients were called for baseline visit (day 0). Medical history, medications, physical examination and vital signs were assessed during hospital visit. *B. coagulans* Unique IS-2 (2billion-CFU/capsule) twice in day (total 4 billion CFU / per day) or placebo (matching in size and appearance, contained only excipient, maltodextrin) twice in a day was given to qualified patients for 4 weeks followed by observation and telephonic follow-up of dose compliance.

- 122 ▪ **Sample size determination:** Statistical software STATA (Version 14, USA) was used for
123 sample calculation. To identify presence of proportion difference the assumption was
124 made that minimum of 118 subjects required to be screened and 94 patients required
125 assessing the endpoint in the study which will reject the null hypothesis.
- 126 ▪ **Intervention:** Fully characterized FDA / DCGI/ FSSAI approved probiotic strain *Bacillus*
127 *coagulans* Unique IS-2 (ATCC PTA-11748, MTCC 5260) was used as an intervention
128 agent in this study for 4 weeks along with placebo as per randomization. The patients
129 were explained to consume one capsule post meal twice a day for 4 weeks along with the
130 SMT. The compliance was ensured by telephonic follow-up and scheduled hospital visits.
- 131 ▪ **Randomization:** Computerized permuted blocks randomization was done in 1:1 ratio and
132 generated by nQuery clinical trial design platform / Sample Size Software. It consisted of
133 two phases: screening, baseline visit 1 (week 0 / day 0), visit 2 (1 week after completing
134 intervention / week 5). The randomization codes were kept blinded.
- 135 ▪ **Outcome measures:** The efficacy outcomes were measured after administration by (i)
136 detection of *Bacillus coagulans* Unique IS-2, (ii) Change in beneficial Lactobacillus and
137 other gut microbiota, (iii) Change in pro and anti-inflammatory cytokines, (iv) Change in
138 symptoms of the disease, (v) Change in serum concentration of serotonin and dopamine,
139 (vi) Changes in physical and psychological parameters. Each participant was requested to
140 answer the designed questionnaire for the assessment of physical, behavioral and
141 psychological parameters as per the Hopkins Symptom Checklist (HSCL): A self-report
142 symptom inventory^{29,30}. Physical parameters including muscle stiffness, heartburn,
143 headache, shakiness, sleep problem, difficulty in completing work, procrastination,
144 overwhelming, feeling of depression, trouble relaxing, nervousness, poor concentration,
145 restlessness and quick temper were evaluated. Parameters were evaluated based on scores,
146 the decrease in the score indicating the reduction in the severity of symptoms and increase
147 in the score indicating an augmentation in the severity of the symptom.
- 148 ▪ **Safety evaluation:** Safety of investigational product was assessed by adverse event
149 reporting. During hospital visit of the patient physical examination, monitoring of vital
150 signs and routine laboratory investigations.
- 151 ▪ **Sample collection and processing:** A stool sample in a sterile container and a blood
152 sample in a plain vial were collected from each enrolled subject before and after
153 intervention. Stool samples were aliquoted and processed for microbial identification and
154 bacterial DNA isolation. Blood samples were processed for serum separation for cytokine
155 assays, serotonin and dopamine concentration.

156 ■ **Microbial culture and identification:** *B. coagulans* Unique IS-2 and *Lactobacillus spp.*
 157 were checked in each patient before and after intervention using different bacterial media.
 158 Mueller Hinton (MH) broth and agar (Difco Laboratory, Detroit, MI) was used for the
 159 cultivation of *Bacillus* strains. Sample were incubated for 24 hours at 37°C in MH broth
 160 and then plated on MH agar plate. de Man, Rogosa and Sharpe (MRS) broth and agar
 161 (Difco Laboratory, Detroit, MI) was used to grow *Lactobacillus*. The stool sample were
 162 incubated for 48 hours at 37°C in MRS broth in Anaerobic Glove Box (Anaerobic
 163 Workstation-Whitley DG250-DonWhitley Scientific, United Kingdom) in anaerobic
 164 condition and then plated on MRS agar plate. The isolated colonies were identified by
 165 standard culture and biochemical method, matrix-assisted laser desorption / ionization-
 166 (MALDI-and the mass analyzer is time-of-flight (TOF) analyzer (bioMérieuxInc, USA)
 167 and molecular method.

168 ■ **Molecular identification of Bacteria:** *B. coagulans* was identified via 16S rRNA
 169 sequencing using published primers: forward 5'-ACAGGGCTTTCAGATACCCG-3' and
 170 reverse 5'-CGGGGATCCGTCCATCAAAA-3'. Sequence similarity was checked using
 171 BLAST, NCBI and it was 96% identical. A known strain of *B. coagulans* Unique IS-2
 172 was used as a positive control. The reaction mixture consisted of 0.5µl of dNTP (10mM),
 173 0.5ul of DNA template (177ng/µl), 2.5 µl of reaction buffer (10X) with MgCL₂, 0.5ul of
 174 each of primers (pm/µl), 0.5µl of 5U/µlTaq DNA polymerase (Thermo Scientific, USA)
 175 and 20 µl of nuclease free H₂O. Denaturation was done at 94°C for 5min, followed by 30
 176 cycles consisting of, 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min which has been
 177 ended by a final amplification step at 72°C for 8min, using the PCR machine (Applied
 178 Biosystems, USA). PCR product was analyzed by the electrophoresis in 1% agarose gel
 179 and gel bands were observed and recorded using via Gel Doc System (BioRad, USA).

180 **Next generation sequencing (NGS) of Gut microbiota-**

181 ■ **Fecal samples collection and DNA isolation:** Fecal samples were collected in sterile
 182 container and processed for DNA isolation. Total DNA was extracted by using QIAamp
 183 DNA Stool Mini Kit (Qiagen) with some modification to increase DNA yield³¹. The
 184 quality and quantity of DNA was checked by Nanodrop (TECAN Nano quant). 16S rRNA
 185 amplicon sequencing was performed using Illumina MiSeq® sequencing system (Illumina,
 186 San Diego, CA, USA).

187 ■ **Sequencing Methodology:** Bacterial 16S rRNA hyper variable regions V3-V4 were
 188 amplified using V3-V4F (CCTACGGGNGGCWGCAG) and V3-V4R
 189 (GACTACHVGGGTATCTAATCC) primers. 25ng of DNA was used for PCR

amplification using KAPA HiFi HotStart Ready Mix. The PCR was performed with standard protocol and the amplicons were purified using Ampure beads to remove unused primers. The amplicon product was amplified with Illumina primers to generate sequencing libraries. Qubit dsDNA assay kit was used for libraries preparation. Sequencing was done using Illumina Miseq with 2x300PE sequencing kit. The sequence data quality was checked using FastQC and MultiQC software.

▪ **Data Analysis:** The analysis was done as per standard methodology³². Only QC passed reads were transferred into mothur and the pairs were aligned. The ambiguous contigs were rejected and duplicates were merged. Chimeric sequences were identified by a known reference and UCHIME algorithm was used. Using Silva v.132 database final filtered contigs were classified into taxonomical outlines and clustered into Operational Taxonomic Unit (OTUs) and abundance was calculated. Alpha diversity was assessed for richness and relative abundance of bacteria. Chao1 and ACE indices were used for richness and Shannon, Simpson, and Fisher were used for both richness and relative abundance. Kruskal-Wallis rank sum test was carried out to identify statistically significant difference among OTUs abundance between groups.

▪ **ELISA for Cytokines, serum serotonin and dopamine:**

Serum samples were tested and quantified for IL10, IL6, IL17, IL23, IL 1 β , TNF, serum serotonin and dopamine as per standard protocol and manufacture's instruction (Fine Test, Fine Biotech Co. Ltd). In brief, standards and test samples were added to 96 well plates and incubated at 37°C for 90 min. After incubation, wells were washed with wash buffer and secondary antibody were added and incubated at 37°C for 60 min. Further, wells were washed and HRP-Streptavidin was added and incubated at 37°C for 30 min. Multiple washing was done with the wash buffer to wash unbound conjugates. TMB substrates were used to visualize HRP enzymatic reaction. Absorbance at 450 nm has been measured using the microplate reader (Nanodrop, Nanoquant Infinite M 200 Pro (Texan, Austria GmbH) and the concentration were calculated.

▪ **Data analysis:** Here we have reported the analysis of data of the patients of ulcerative colitis (UC). Data from 48 subjects in treatment group and 49 subjects in placebo group were analysed. Statistical analysis was done by STATA statistical software (Version 14, USA). Statistical evaluation of parameters was assessed by Chi-square / two sample *t*-test and *p* value < 0.05 was considered as statistically significant.

‘CONSORT’ Flow Chart

Results

Survival of *Bacillus coagulans* Unique IS2 in the gut

The samples of the enrolled subjects in the both treatment and placebo group were assessed for the presence of *Bacillus coagulans* Unique IS-2 before and after treatment. No *B coagulans* was detected in pre-treatment sample in both the groups. In the probiotic treated group *B coagulans* was detected in 65.21 % subjects by microbial culture method and 76.08 % subjects by molecular method which was significant as compared to placebo ($p < 0.0001$). The samples from the subjects of placebo group were also assessed for the presence of *B coagulans* with no *B coagulans* being detected in placebo group by both microbial and molecular methods. These results indicate that the probiotic strain *B coagulans* Unique IS-2 was able to survive in GI tract of recruited IBD patients.

Detection of beneficial Lactobacilli by microbial culture method

The samples of the enrolled IBD patients in both probiotic treated group and placebo group were assessed for the presence of beneficial Lactobacilli, before and after intervention. Results revealed that in the probiotic treated group, beneficial *Lactobacilli* were detected in 54.34 % and 78.26 % patients before and after intervention respectively. In the placebo group beneficial *Lactobacilli* were detected in 52.08 % and 47.91 % of patients before and after intervention respectively. The detection of beneficial *Lactobacilli* after intervention in the probiotic treated group was significantly high ($p < 0.01$) which indicated that the probiotic strain *Bacillus coagulans* Unique IS-2 was able to enhance the presence of beneficial *Lactobacilli* in recruited IBD patients.

Next generation Sequencing (NGS) and Metagenomic analysis of gut microbiota

Phyla: Operational Taxonomic Unit (OTUs) were calculated for different bacterial taxon including phyla, class, orders, families, genera and species before and after intervention in both probiotic treated and placebo group. Analysis revealed phylum Firmicutes Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were abundant in both the groups. The average % OTUs of phylum *Firmicutes* were in 33.13% and 36.23% in pre and post intervention sample respectively in treatment group and 37.90% and 42.89% in placebo group. The average % OTUs of phylum *Bacteroidetes* were in 40.12% and 40.28% in pre and post intervention sample respectively in treatment group and 32.49% and 40.28% in pre and post intervention sample respectively in placebo group. OTUs of phylum *Bacteroidetes* were significantly increased in post intervention sample in

placebo group. The average % OTUs of phylum *Proteobacteria* were in 12.90% and 7.50% in pre and post intervention sample respectively in treatment group and 16.75% and 6.21% in placebo group. The average % OTUs of phylum *Actinobacteria* were in 6.64% and 4.29% in pre and post intervention sample respectively in treatment group and 8.62% and 2.04% in placebo group. Decrease in OTUs of phylum *Proteobacteria* and phylum *Actinobacteria* was significant in the treatment group. The average % OTUs of phylum *Euryarchaeota* were in 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and 2.03% and 0.55% in placebo group. OTUs of phylum *Euryarchaeota* were increased in post intervention sample in treatment group and decreased in placebo group. The average % OTUs of phylum *Verrucomicrobia* were in 0.01% and 0.04% in pre and post intervention sample respectively in treatment group and 0.96% and 0.10% in placebo group. OTUs of phylum *Verrucomicrobia* were increased in post intervention sample in treatment group and decreased in placebo group.

Figure 1: Abundance of major bacterial phyla

Class: The average % OTUs of class *Bacteroidia* were 40.11% and 40.27% in pre and post intervention sample respectively in treatment group and 32.48% and 43.63% pre and post intervention sample respectively in placebo group. An increase in OTUs of class *Bacteroidia*

was significant in the placebo group. The average % OTUs of class Clostridia were 15.20% and 22.09% in pre and post intervention sample respectively in treatment group and 20.79% and 28.82% in pre and post intervention sample respectively in placebo group. The average % OTUs of class Gammaproteobacteria were 12.87% and 7.41% in pre and post intervention sample respectively in treatment group and 16.72% and 6.16% respectively in placebo group. The average % OTUs of class Negativicutes were 7.96% and 6.35% in pre and post intervention sample respectively in treatment group and 3.49% and 7.22% respectively in placebo group. A decrease was observed in OTUs of class Negativicutes in post intervention samples of treatment group and an increase in post intervention samples in placebo group. The average % OTUs of class Methanobacteria were 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and 2.03% and 0.55% in placebo group. An increase in OTUs of class Methanobacteria in post intervention samples was observed in treatment group and decrease in OTUs of class Methanobacteria in placebo group. The average % OTUs of class Actinobacteria were 3.49% and 1.81% in pre and post intervention sample respectively in treatment group and 7.76% and 1.64% pre and post intervention sample respectively in placebo group.

Figure 2: Abundance of major bacterial classes

Order: The average % OTUs of Bacteroidales were 39.94% and 40.03% in pre and post intervention sample respectively in treatment group and 32.37% and 43.46% in placebo group. A significant increase in OTUs of order Bacteroidales in post intervention samples was observed in placebo group. The average % OTUs of order Clostridiales was 15.19% and 22.08% in pre and post intervention sample respectively in treatment group and 20.79% and 28.81% in placebo group. The average % OTUs of order Selenomonadales was 8.02% and 6.30 % in pre and post intervention sample respectively in treatment group and 3.49% and 7.22% in placebo group. A decrease in OTUs of order Selenomonadales in post intervention samples in treatment group and increase in post intervention samples in placebo group. The average % OTUs of order Lactobacillales was 1.67% and 2.49% in pre and post intervention sample respectively in treatment group and 10.66% and 3.82% in placebo group. An increase in OTUs of order Lactobacillales was observed in post intervention samples in treatment group and decrease in post intervention samples in placebo group. The average % OTUs of order Erysipelotrichales was 7.00% and 5.03% in pre and post intervention sample respectively in treatment group and 2.48 % and 2.48% in placebo group. A decrease in OTUs of order Erysipelotrichales in post intervention samples in treatment group and increase in placebo group were observed. The average % OTUs of order Bifidobacteriales were 1.74% and 3.55% in pre and post intervention sample respectively in treatment group and 7.71% and 1.61% respectively in placebo group. An increase in OTUs of order Bifidobacteriales in post intervention samples in treatment group and decrease in placebo group were observed.

Figure 3: Abundance of major bacterial orders

350

351 **Family:** The average % OTUs of family Prevotellaceae was 32.66% and 33.20% in pre and
352 post intervention sample respectively in treatment group and 8.62% and 31.96% in placebo
353 group. Significant increase was observed in OTUs of family Prevotellaceae in post
354 intervention samples in placebo group. The average % OTUs of family Ruminococcaceae
355 was 8.22% and 11.99% in pre and post intervention sample respectively in treatment group
356 and 12.34% and 12.23% in placebo group. Increase in OTUs of family Ruminococcaceae in
357 post intervention samples in treatment group and decrease in placebo group. The average %
358 OTUs of family Bacteroidaceae was 4.09% and 4.58 % in pre and post intervention sample
359 respectively in treatment group 22.85% and 9.44% in placebo group. Increase in OTUs of
360 family Bacteroidaceae in post intervention samples in treatment group and decrease in
361 placebo group were observed. The average % OTUs of family Lachnospiraceae was 6.14 %
362 and 8.40 % in pre and post intervention sample respectively in treatment group and 6.79 %
363 and 13.48 % respectively in placebo group. The average % OTUs of family Veillonellaceae
364 was 7.47% and 5.72 % in pre and post intervention sample respectively in treatment group
365 and 3.49 % and 7.15% in placebo group. Decrease in OTUs of family Veillonellaceae in post
366 intervention samples in treatment group and increase in placebo group were observed. The

average % OTUs of family Enterobacteriaceae was 4.69 % and 3.14 % in pre and post intervention sample respectively in treatment group and 9.79% and 2.41 % respectively in placebo group. A significant decrease was observed in OTUs of family Enterobacteriaceae in post intervention samples in placebo group. The average % OTUs of family Lactobacillaceae was 1.12% and 2.03% in pre and post intervention sample respectively in treatment group and 6.36 % and 3.22 % respectively in placebo group. Increase in OTUs of family Lactobacillaceae in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of family Bifidobacteriaceae was 1.74% and 3.55% in pre and post intervention sample respectively in treatment group and 7.71% and 1.61% respectively in placebo group. Increase in OTUs of family Bifidobacteriaceae in post intervention samples in treatment group and decrease in placebo group were observed.

Figure 4: Abundance of major bacterial families

Genera: The average % OTUs of genus *Prevotella* were 26.37% and 22.10% in pre and post intervention sample respectively in treatment group and 10.28% and 25.57% respectively in placebo group. Decrease in OTUs of genus *Prevotella* in post intervention samples in treatment group and an increase in placebo group was observed. The average % OTUs of

genus *Bacteroides* were 4.88% and 6.13% in pre and post intervention sample respectively in treatment group and 19.96% and 7.89% respectively in placebo group. An increase in OTUs of genus *Bacteroides* in post intervention samples in treatment group and decrease in placebo group were observed. Average % OTUs of genus *Faecalibacterium* were 6.56% and 6.87% in pre and post intervention sample respectively in treatment group and 9.23% and 8.01% respectively in placebo group. An increase in OTUs of genus *Faecalibacterium* in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus *Lactobacillus* were 1.21% and 2.59% in pre and post intervention sample respectively in treatment group and 7.33% and 3.49% respectively in placebo group. An increase in OTUs of genus *Lactobacillus* in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus *Bifidobacterium* were 1.67% and 4.44% in pre and post intervention sample respectively in treatment group and 6.03% and 1.42% respectively in placebo group. An increase in OTUs of genus *Bifidobacterium* in post intervention samples in treatment group and decrease in placebo group were observed. The average % OTUs of genus *Bacillus* were 0.01% and 0.04% in pre and post intervention sample respectively in treatment group and 0.001% and 0.001% respectively in placebo group. OTUs of Genus *Bacillus* in post intervention samples in treatment group were high while OTUs of genus *Bacillus* in placebo group were very low. The average % OTUs of genus *Escherichia* were 3.61% and 1.24% in pre and post intervention sample respectively in treatment group and 11.06% and 1.81% in placebo group. The average % OTUs of genus *Sutterella* were 3.05% and 2.22% in pre and post intervention sample respectively in treatment group and 3.60% and 1.68 % in placebo group. The average % OTUs of genus *Dialister* were 3.37% and 1.98% in pre and post intervention sample respectively in treatment group and 0.09% and 3.66% respectively in placebo group. A decrease in OTUs of genus *Dialister* was observed in post intervention samples in treatment group and increase in placebo group. The average % OTUs of genus *Megamonas* were 1.39% and 2.17% in pre and post intervention sample respectively in treatment group and 0.73% and 0.001% respectively in placebo group. An increase in OTUs of genus *Megamonas* was observed in post intervention samples in treatment group and decrease in placebo group. The average % OTUs of genus *Roseburia* were 0.82% and 0.45% in pre and post intervention sample respectively in treatment group and 1.18% and 2.46% in placebo group. A decrease in OTUs of genus *Roseburia* was observed in post intervention samples in treatment group and increase in placebo group. The average % OTUs of genus *Megasphaera* were 2.37% and 0.36% in pre and post intervention sample respectively in treatment group

and 2.02% and 1.97% in placebo group. A decrease in OTUs of genus *Megasphaera* was observed in post intervention samples in both treatment and placebo group. The average % OTUs of genus *Lachnospira* were 0.42% and 0.34% in pre and post intervention sample respectively in treatment group and 1.49% and 2.83% in placebo group. An increase in OTUs of genus *Lachnospira* was observed in post intervention samples in treatment group and decrease in placebo group. The average % OTUs of genus *Blautia* were 0.25% and 0.40% in pre and post intervention sample respectively in treatment group and 0.12% and 0.25% in placebo group. An increase in OTUs of genus *Blautia* was observed in post intervention samples in both treatment and placebo group. The average % OTUs of genus *Alistipes* were 0.08% and 0.37% in pre and post intervention sample respectively in treatment group and 0.12% and 0.04% in placebo group. An increase in OTUs of genus *Alistipes* in post intervention samples in treatment group and decrease in placebo group were observed.

Figure 5: Abundance of major bacterial genera

Cytokines levels

Serum concentrations of different cytokines were assessed before and after intervention and results are expressed as Mean $\pm$ SD. In the probiotic treated group serum levels of IL10 were 3.23 ± 1.22 pg/ml and 9.25 ± 2.6 pg/ml before and after intervention respectively with the difference being significant ($p < 0.05$). In the placebo group serum IL10 levels were 2.47 ± 1.19 pg/ml and 2.97 ± 1.67 pg/ml before and after intervention respectively, this difference was not significant ($p = ns$). Results indicated that the secretion of IL-10 in IBD-UC patients was increased in *B coagulans* Unique IS2 group. In the treatment group serum IL6 levels were 34.13 ± 6.8 pg/ml and 17.64 ± 5.2 pg/ml before and after intervention respectively with the difference being significant ($p < 0.05$). In the placebo group serum IL6 levels were 35.85 ± 7.6 pg/ml and 28.49 ± 6.4 pg/ml before and after intervention respectively and this difference was not significant ($p = ns$). The observed results indicated that the secretion of IL-6 in IBD-UC patients was decreased in *B coagulans* Unique IS2 group. In the probiotic treated group, serum IL17 levels were 42.82 ± 6.9 pg/ml and 28.57 ± 5.4 pg/ml before and after intervention respectively with the difference being significant ($p < 0.05$). In the placebo group serum IL17 levels were 36.73 ± 13.73 pg/ml and 33.96 ± 14.74 pg/ml before and after intervention respectively with the difference not being significant ($p = ns$). The observed results indicated that the secretion of serum IL-17 was decreased in IBD-UC patients in the probiotic group. In the probiotic treated group serum IL23 levels were 938.39 ± 56.57 pg/ml and 842.20 ± 69.43 pg/ml before and after intervention respectively with the difference not being significant. In the placebo group serum IL23 levels were 951.59 ± 61.31 pg/ml and 932.02 ± 43.30 pg/ml before and after intervention respectively with the difference not being significant ($p = ns$).

In the treatment group serum IL-1 β levels were 358.58 ± 39.29 pg/ml and 267.28 ± 33.88 pg/ml before and after intervention respectively with the difference being significant ($p < 0.05$). In the placebo group serum IL-1 β levels were 363.93 ± 35.57 pg/ml and 382.59 ± 37.50 pg/ml before and after intervention respectively with the difference not being significant ($p = ns$). The observed results indicated that the secretion of serum IL-1 β in IBD-UC patients was increased in *B coagulans* Unique IS2 group. In the treatment group serum TNF- α levels were 80.33 ± 13.68 pg/ml and 69.16 ± 14.79 pg/ml before and after intervention respectively with the difference not significant whereas in the placebo group serum TNF- α levels were 76.35 ± 14.72 pg/ml and 79.39 ± 13.8 pg/ml before and after intervention respectively with the difference not being significant.

Serum serotonin and dopamine levels:

In the treatment group serum serotonin level were 121.48 ± 15.52 ng/ml and 111.30 ± 17.74 ng/ml before and after intervention and the difference was not significant. In the placebo group serotonin level were 118.12 ± 19.25 ng/ml and 109.88 ± 11.23 ng/ml before and after intervention and the difference was not significant. In the treatment group serum dopamine level were 8.51 ± 2.52 pg/ml and 11.74 ± 2.25 pg/ml before and after intervention and the difference was not significant. In the placebo group dopamine level were 8.48 ± 2.89 pg/ml and 10.89 ± 2.99 pg/ml, before and after intervention and the difference was not significant. There were changes in serotonin and dopamine levels in the subjects before and after intervention but the difference was not significant.

Table 1: Serum Cytokines, serotonin and dopamine levels in pre and post intervention samples in treatment and placebo group

Cytokine (pg/ml)	<i>Bacillus coagulans</i> Unique IS2 group			Placebo group		
	Pre	Post	P value	Pre	Post	P value
IL-10	3.23 ± 1.22	9.25 ± 2.6	<0.05	2.47 ± 1.19	2.97 ± 1.67	NS
IL-6	34.13 ± 6.8	17.64 ± 5.2	<0.05	35.85 ± 7.6	28.49 ± 6.4	NS
IL-17	42.82 ± 6.9	28.57 ± 5.4	<0.05	36.73 ± 13.7	33.96 ± 14.74	NS
IL-23	938.39 ± 56.5	842.20 ± 69.4	NS	951.59 ± 61.3	932.02 ± 43.30	NS
IL-1 β	358.58 ± 39.2	267.28 ± 33.8	<0.05	363.93 ± 35.5	382.59 ± 37.50	NS
TNF- α	80.33 ± 13.6	69.16 ± 14.7	NS	76.35 ± 14.7	79.39 ± 13.8	NS
Serotonin (ng/ml)	121.48 ± 15.5	111.30 ± 17.7	NS	118.12 ± 19.2	109.88 ± 11.23	NS
Dopamine (pg/ml)	8.51 ± 2.52	11.74 ± 2.2	NS	8.48 ± 2.89	10.89 ± 2.99	NS

Effect on disease symptoms

Symptoms of disease were assessed based on patient complaint and SCCAI score was calculated for IBD-UC patients as per standard protocol. The decrease in the SCCAI score indicates the reduction in the severity of symptoms and increase in the score indicates the augmentation in the severity of the symptom of UC. In this study reduction of 1 value in SCCAI score was considered as decrease in SCCAI score. The SCCAI score was decreased post intervention in 43.75 % of the patients in the probiotic treated group which was significantly high ($p < 0.05$) as compared to placebo where the decrease in SCCAI score was reported in 28.57 % patients.

Effect on physical, behavioral and psychological parameters

The enrolled subjects were assessed before and after intervention for the different physical symptoms, behavioral and psychological symptoms including stiff or tense muscles, heartburn, headache, shakiness or tremor, sleep problem, difficulty in completing work, procrastination, overwhelming, feeling of depression, trouble relaxing, nervousness, poor concentration, quick temper and restlessness. All the symptoms were evaluated based on scores, the decrease in the score indicates the reduction in the severity of symptoms and increase in the score indicates the augmentation in the severity of the symptom. In this study the complaint of muscles stiffness was reduced post intervention in 41.66 % and 29.16 % subjects in the treatment and placebo group respectively and the difference between the groups was significant ($p < 0.05$). The complaint of heartburn was reduced post intervention in 43.75 % and 31.25 % subjects in the treatment and placebo group respectively and the difference between the groups was significant ($p < 0.05$). The complaints of headache were reduced post intervention in 37.5 % and 33.33 % subjects in the probiotic and placebo group respectively with no significant difference between groups. The complaint of shakiness or tremor was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and placebo group with no significant difference between groups.

The complaint of sleep problem was reduced post intervention in 41.66 % and 27.08 % subjects in the treatment and placebo group respectively with the difference between groups being significant ($p < 0.05$). The complaint of procrastination was reduced in 31.25 % subjects and 35.4 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of difficulty in completing work or assignments was decreased post intervention in 37.5 % subjects and 27.08 % subjects in the probiotic treated and placebo group respectively with the difference between groups being significant ($p < 0.05$). The complaints of overwhelming was reduced post intervention in 41.66 % and 31.25 % subjects in the treatment and placebo group respectively and the difference between placebo and treatment groups was significant ($p < 0.05$). The complaints of trouble relaxing was reduced post intervention in 37.5 % and 27.08 % subjects in the treatment group and placebo group respectively with the difference between groups being significant ($p < 0.05$). The complaint of nervousness was reduced post intervention in 33.33 % and 29.16 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of depression was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and placebo group respectively with no significant difference between groups. The complaints of poor concentration was reduced

post intervention in 47.91 % and 33.3 % subjects in the treatment group and placebo group respectively with the difference between groups being significant ($p < 0.05$). The complaints of quick temper was reduced post intervention in 45.83 % and 39.58 % subjects in the treatment group and placebo group respectively with no significant difference. The complaints of restlessness was reduced post intervention in 47.91 % and 35.4 % subjects in the treatment group and placebo group respectively with the difference between groups being significant ($p < 0.05$). The observed results exhibited improvement in various physical, behavioral and psychological symptoms of enrolled IBD subjects in the treatment group.

Table 2: Post intervention decrease in symptoms in the enrolled subjects for different physical, behavioral and psychological parameters

Physical, behavioural and psychological parameters	Post intervention decrease in symptoms (% of total subjects)		
	<i>Bacillus coagulans</i> Unique IS2 group	Placebo group	P value
Muscles stiffness	41.66 %	29.16 %	<0.05
Heartburn	43.75	31.25 %	<0.05
Headache	37.5 %	33.33 %	NS
Shakiness or tremor	33.33 %	31.25 %	NS
Sleep problem	41.66 %	27.08 %	<0.05
Procrastination	31.25 %	35.4 %	NS
Difficulty in completing work or assignments	37.5 %	27.08 %	<0.05
Overwhelming	41.66 %	31.25 %	<0.05
Trouble relaxing	37.5 %	27.08 %	<0.05
Nervousness	33.33 %	29.16 %	NS
Depression	33.33 %	31.25 %	NS
Poor concentration	47.91 %	33.3 %	<0.05
Quick temper	45.83 %	39.58 %	NS
Restlessness	47.91 %	35.4 %	<0.05

Safety evaluations: During and after intervention no adverse events were observed, recorded and reported in the study which further established the safety of *B coagulans* Unique IS2.

Discussion

Targeted microbiota intervention through probiotics and fecal microbiota transplantation are considered as effective therapeutic methods for IBD^{12,33}. Mechanisms of action of probiotics in IBD prevention include increase in beneficial bacteria, inhibition of pathogenic bacteria, immuno-modulation, augmentation of anti-inflammatory responses and enhancement of the intestinal barrier function¹⁴. *Bacillus* species are high heat resistance, acid tolerance and they can survive considerably better than other probiotics in gastric conditions^{34,35}. *B. coagulans* Unique IS-2 is a non-toxic commercial probiotic strain with proven safety and efficacy, long shelf life and stability at room temperature²⁴. Whole genome sequence analysis of *B. coagulans* Unique IS-2 has corroborated its safety with the absence of any toxin genes³⁶. In this study, no severe adverse event was reported, which establish the safety of *B. coagulans* Unique IS-2. Safety and therapeutic efficacy of *B. coagulans* Unique IS-2 has been proven in different disease including Irritable Bowel Syndrome in adult²⁷ and children²⁵, acute-diarrhea²⁶, abdominal pain³⁷, constipation²⁷, oral health³⁸, bacterial vaginosis²⁶, anti-hypercholesterolemic effect²² and liver cirrhosis. This strain also showed anti-inflammatory²⁴ and anti-proliferative effects³⁹.

Post intervention, significant detection of *Bacillus coagulans* in the probiotic treated group demonstrating that this probiotic strain was able to survive in GI tract of IBD patients. Beneficial bacteria provide protection to host against colonization of harmful bacteria and suppress the growth of pathogens by imposing competition for shared niches and nutrients⁴⁰. Results of the present study indicated that *B. coagulans* Unique IS-2 was able to modulate the gut microbiota by increasing beneficial bacteria. Another study also reported that consumption of *B. coagulans* was capable of restoring the microbial imbalance⁴¹ and able to increase populations of *Lactobacillus* and *Bifidobacteria*^{42,43} possibly by consuming free oxygen in the intestine and reduces redox reactions, creating an unfavorable anaerobic and acidic environment to various pathogens⁴³.

Results of the metagenomics analysis revealed that phylum Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were abundant in both the study group which are earlier reported dominated in Indian gut^{44,45}. An increase in the abundance of phylum Firmicutes and Bacteroidetes was observed in post intervention sample in both groups. Decrease in abundance of phylum Proteobacteria and Actinobacteria was observed in post intervention sample in both groups. Other studies also reported decrease in Bacteroides and Firmicutes and increase in Proteobacteria and Actinobacteria in GI

disease^{31,46}. It is believed that inflammation is an oxidative state which might promote the outgrowth of aerotolerant taxa such as Proteobacteria and Actinobacteria⁴⁷.

The abundance of *Lactobacillus*, *Bifidobacterium* and *Bacillus* genera were increased in post intervention samples in treatment group and decrease in placebo group. *Lactobacillus* and *Bifidobacterium* are among the first colonizers of newborns⁴⁸ and are known for their beneficial effects⁴⁹. The observed high abundance of *Lactobacillus*, *Bifidobacterium* and *Bacillus* genera in treatment group indicated that given probiotic help the gut in restoring these beneficial bacteria. Other studies reported decreased abundance of *Faecalibacterium* in IBD^{50,51}. We observed an increase in abundance of genus *Faecalibacterium* in post intervention samples in treatment group and decrease in placebo group which indicates the given probiotic help the gut in restoring them. Bacterial genera *Lactobacillus*, *Bifidobacterium*, and *Faecalibacterium* have been reported to be protective for mucosal inflammation in the host^{11,52} via several mechanisms, including the up-regulation of the anti-inflammatory cytokine, and down-regulation of inflammatory cytokines⁵³. Studies reported decrease in the genera *Bacteriodes* in IBD^{14,54}. We observed an increase in abundance of genus *Bacteriodes* in post intervention samples in treatment group and decrease in placebo group which indicates that the given probiotic intervention may help to restore the genus *Bacteriodes* in enrolled IBD patients. A decrease in the abundance of bacterial genera *Dialister*, *Roseburia*, *Megasphaera* was observed in post intervention samples in treatment group and increase in placebo group. A decrease in the abundance of *Blautia* species in the IBD patients was reported⁵⁵. We observed an increase in OTUs of genus *Blautia* in post intervention samples in both treatment and placebo group. An increase in abundance of genus *Alistipes* in post intervention samples in treatment group and decrease in placebo group were observed. Gut microbiota study in the IBD patients reported that some of the *Faecalibacterium*, *Bacteriodes* and *Alistipes* species have shown significant contribution to metabolic pathway transcription⁵⁶. The abundance of some of bacterial taxon was low but these may play important role in gut function as reported earlier⁵⁷.

The improper host immune response against GI microbiota is considered to be the main reason in causing severe inflammation⁴⁰. Studies have reported the changes in the serum levels of anti-inflammatory cytokine (IL-10) and pro-inflammatory cytokines (IL-6, IL-12, TNF- α , INF- γ) in GI disorders⁵⁸. However, the serum cytokine profiling of IBD patients remains less reported. In the present study significant increase was observed in IL-10 levels in treatment group which indicated that the probiotic strain was able to increase the secretion of IL-10 in IBD patients in the treatment group. Other studies have reported the association of

IBD patients with anti-inflammatory cytokines IL-10⁵⁹ and IL-10 secretion increased during disease recovery in IBD patients⁶⁰. It is also reported that inactivation of IL-10 leads to increased release of pro-inflammatory cytokines⁶¹.

In the present study we observed the significant decrease in IL6 ($p < 0.05$), IL17 ($p < 0.05$), IL23 ($p < 0.05$), and IL-1 β ($p < 0.05$), TNF- α in treatment group which indicated the probiotic intervention was able to modulate the secretion of pro-inflammatory cytokines. Previous studies have reported increased expression of IL-6 may be an intestinal inflammatory mediator of IBD⁶⁴. Studies have reported that the expression of IL-6 was predominantly detected in IBD and an association between serum levels of IL-6 and disease activity⁶². A study reported IL6 in active UC 26 $\pm$ 10 pg/ml and in inactive UC < 10 pg/ml⁶³ and this suggested that increased expression of IL-6 may be an intestinal inflammatory mediator of IBD. IL-17 induces the production of many other pro-inflammatory cytokines, including IL-6, TNF- α , and IL-1 β , which leads to localizing and amplifying inflammation. IL-17 was reported to be increased in intestinal tissue and serum of IBD patients^{64,65}. IL-1 β is a pro-inflammatory cytokines play important role in the inflammation in patients with IBD and an elevation in IL-1 β levels are associated with increased disease severity⁶⁶⁻⁶⁸. Studies reported that the improper level of serotonin and dopamine increases the severity of IBD⁶⁹. Serum serotonin and dopamine were also evaluated in this study but no significant change was observed in both groups.

Results of the study indicated that *B coagulans* Unique IS-2 along with SMT was able to reduce the severity of symptom and improve physical and psychological parameters in IBD patient in the treatment group. These results are similar to another study which reported that a probiotic mixture (VSL#3) reduced the expression of inflammatory cytokines and the severity of disease in UC patients⁷⁰. A meta-analysis also reported that probiotics can benefit IBD treatment during combined use of probiotics and standard therapy⁷¹. A study with *B. coagulans* Unique IS-2 in children with functional abdominal pain indicated reduction of abdominal pain in the probiotic treated group³⁷. Another study reported *B. coagulans* Unique IS-2 was effective in the treatment of IBS with a significant decrease in the intensity of pain in the probiotic treated group²⁵. Probiotics can reduce inflammation and disease symptoms by modulation of the mucosal immune system, increased intestinal barrier function, competitive prohibition of pathogens, production of antimicrobial factors⁷² amplification of the intestinal tight junctions to stabilize the permeability, normalize bowel movements and reduce visceral hypersensitivity⁷³⁻⁷⁵.

Summary and Conclusion

The results of the study showed that the *B coagulans* Unique IS-2 is able to survive in GI tract of IBD patients. *B. coagulans* Unique IS-2 was able to enhance bacterial genera *Lactobacillus*, *Bifidobacterium*, *Faecalibacterium*, *Bacteroides*, *Megamonas*, *Lachnospira*, *Blautia* and *Alistipes* in post intervention samples in the treatment group. A decrease in bacterial genera *Sutterella*, *Dialister*, *Roseburia* and *Megasphaera* was observed in post intervention samples in the treatment group. Variable alterations were also observed in the abundance of different bacterial taxon including phylum, class, order, family, and genus in the post intervention sample of the treatment group. *B coagulans* Unique IS-2 was able to modulate the secretion of serum cytokines in IBD patients. The level of IL-10 was increased significantly post intervention in treatment group. The secretion of cytokines, IL-6, IL-1 β , TNF- α , IL -17 and IL -23 were variably decreased post intervention in the treatment group. No significant change in serum serotonin and dopamine was observed in both treatment and placebo groups. A reduction in the severity of symptoms of disease and significant improvement in the physical and psychological parameter were observed post intervention in enrolled subjects in the treatment group. Observed results demonstrated that *B coagulans* Unique IS2 showed beneficial effect in IBD-UC patients when administered along with standard medical treatment (SMT). Study was registered with Clinical Trials Registry India (CTRI) - (CTRI registration No.- CTRI/2019/11/022087).

Conflict of interest statement: RSM and JN are employed by manufacturer of probiotics (Unique Biotech Ltd) and they wish to state that the study was conducted independently with no intervention on their part during the study. All other authors declare no conflict of interest.

Author Contribution: VDB- Recruited the subjects, carried out experiments, analyzed data and wrote final manuscript, DD - carried out experiments and analyzed the data, PS - carried out experiments and analyzed the data. SK clinical assessment and monitoring of subjects, RSM, JN – drafted study proposal and manuscript, VA- clinical assessment and monitoring of subjects, designed the trial, supervised the study. RC -conceptualizes the study, finalized study proposal, designed the trial and supervised the study. All the authors read and revised the manuscript and approve the final manuscript.

Acknowledgement: Authors acknowledge the financial support from Unique Biotech Ltd, Hyderabad, India. Help of Mr. Surender Singh (Laboratory Technician) in microbial culture media and reagent preparation is also acknowledged.

References

1. Acharyya BC. Incidence of Inflammatory Bowel Disease in a Tertiary Centre of Eastern India. *ARGH*; 9. Epub ahead of print 26 July 2018. DOI: 10.19080/ARGH.2018.09.555774.
2. Kedia S, Ahuja V. Is the emergence of inflammatory bowel disease a prime example of 'the third epidemiological transition'? *Indian J Gastroenterol* 2018; 37: 183–185.
3. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. *Intest Res* 2017; 15: 138–141.
4. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East. *Inflamm Intest Dis* 2017; 2: 102–115.
5. Kim YS, Jung S-A, Lee K-M, et al. Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. *Intest Res* 2017; 15: 338–344.
6. Sigall-Boneh R, Levine A, Lomer M, et al. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. *J Crohns Colitis* 2017; 11: 1407–1419.
7. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. *Curr Pharm Des* 2014; 20: 1082–1096.
8. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. *Curr Mol Med* 2008; 8: 247–252.
9. Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. *Immune Netw* 2017; 17: 25–40.
10. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018; 11: 1–10.
11. Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. *Front Microbiol* 2018; 9: 2247.
12. Dong L-N, Wang M, Guo J, et al. Role of intestinal microbiota and metabolites in inflammatory bowel disease. *Chin Med J (Engl)* 2019; 132: 1610–1614.
13. Sun Y, Li L, Xia Y, et al. The gut microbiota heterogeneity and assembly changes associated with the IBD. *Sci Rep* 2019; 9: 440.
14. Khan I, Ullah N, Zha L, et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. *Pathogens* 2019; 8: 126.
15. Manocha M, Khan WI. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. *Clin Transl Gastroenterol* 2012; 3: e13.
16. O'Mahony SM, Clarke G, Borre YE, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav Brain Res* 2015; 277: 32–48.
17. Tolstanova G, Deng X, Ahluwalia A, et al. Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease. *Dig Dis Sci* 2015; 60: 2963–2975.
18. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. *Nat Rev Gastroenterol Hepatol* 2009; 6: 306–314.

19. Reber SO. Stress and animal models of inflammatory bowel disease—An update on the role of the hypothalamo–pituitary–adrenal axis. *Psychoneuroendocrinology* 2012; 37: 1–19.
20. Sudha M, Chauhan P, Dixit K, et al. Molecular Typing and Probiotic Attributes of a New Strain of *Bacillus coagulans* - Unique IS-2: a Potential Biotherapeutic Agent. *undefined*, <https://www.semanticscholar.org/paper/Molecular-Typing-and-Probiotic-Attributes-of-a-New-Sudha-Chauhan/f8bbf999bc57cb022d282e9ad13442f877914db7> (2010, accessed 28 July 2021).
21. Konuray G, Erginkaya Z. Potential Use of *Bacillus coagulans* in the Food Industry. *Foods* 2018; 7: 92.
22. Ratna Sudha M, Radkar N, Maurya A. Effect of supplementation of probiotic *Bacillus coagulans* unique IS-2 (ATCC PAT-11748) on hypercholesterolemic subjects: A clinical study. *International Journal of Probiotics and Prebiotics* 2011; 6: 89–94.
23. Ratna Sudha M, Bhonagiri S. Efficacy of *Bacillus coagulans* strain unique IS-2 in the treatment of patients with acute diarrhea. *International Journal of Probiotics and Prebiotics* 2012; 7: 33–37.
24. Sudha RM, Sunita M, Sekhar BM. Safety studies of *Bacillus coagulans* unique IS-2 in rats: Morphological, biochemical and clinical evaluations. *International Journal of Probiotics & Prebiotics* 2016; 11: 43+.
25. Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of *Bacillus coagulans* Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. *Benef Microbes* 2018; 9: 563–572.
26. Ratna Sudha M, Yelikar KA, Deshpande S. Clinical Study of *Bacillus coagulans* Unique IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis. *Indian J Microbiol* 2012; 52: 396–399.
27. Madempudi RS, Neelamraju J, Ahire JJ, et al. *Bacillus coagulans* Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. *Probiotics Antimicrob Proteins* 2020; 12: 335–342.
28. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. *Gut* 1998; 43: 29–32.
29. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL). *Psychological Measurements in Psychopharmacology* 1974; 7: 79–110.
30. Kleppang AL, Hagquist C. The psychometric properties of the Hopkins Symptom Checklist-10: a Rasch analysis based on adolescent data from Norway. *Fam Pract* 2016; 33: 740–745.
31. Bamola VD, Ghosh A, Kapardar RK, et al. Gut microbial diversity in health and disease: experience of healthy Indian subjects, and colon carcinoma and inflammatory bowel disease patients. *Microb Ecol Health Dis* 2017; 28: 1322447.
32. Ahmed N, Daniel B, Varghese J, et al. Oropharyngeal microbiome of an HIV-positive patient. *Microbial Pathogenesis* 2020; 139: 103805.
33. Hudson LE, Anderson SE, Corbett AH, et al. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. *Clin Microbiol Rev* 2017; 30: 191–231.

34. Hyronimus B, Le Marrec C, Sassi AH, et al. Acid and bile tolerance of spore-forming lactic acid bacteria. *Int J Food Microbiol* 2000; 61: 193–197.
35. Keller D, Verbruggen S, Cash H, et al. Spores of *Bacillus coagulans* GBI-30, 6086 show high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract. *Benef Microbes* 2019; 10: 77–87.
36. Upadrasta A, Pitta S, Madempudi RS. Draft Genome Sequence of the Spore-Forming Probiotic Strain *Bacillus coagulans* Unique IS-2. *Genome Announc* 2016; 4: e00225-16.
37. Saneian H, Pourmoghaddas Z, Roohafza H, et al. Synbiotic containing *Bacillus coagulans* and fructo-oligosaccharides for functional abdominal pain in children. *Gastroenterol Hepatol Bed Bench* 2015; 8: 56–65.
38. K MJ, Shenoy N, Talwar A, et al. Clinical effect of pro-biotic containing *Bacillus coagulans* on plaque induced gingivitis: A randomised clinical pilot study. *Journal of Health and Allied Sciences NU* 2017; 07: 007–012.
39. Madempudi RS, Kalle AM. Antiproliferative Effects of *Bacillus coagulans* Unique IS2 in Colon Cancer Cells. *Nutr Cancer* 2017; 69: 1062–1068.
40. Kho ZY, Lal SK. The Human Gut Microbiome - A Potential Controller of Wellness and Disease. *Front Microbiol* 2018; 9: 1835.
41. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* 2012; 307: 1959–1969.
42. Ara K, Meguro S, Hase T, et al. Effect of Spore-bearing Lactic Acid-forming Bacteria (*Bacillus coagulans* SANK 70258) Administration on the Intestinal Environment, Defecation Frequency, Fecal Characteristics and Dermal Characteristics in Humans and Rats. *Microbial Ecology in Health and Disease* 2002; 14: 4–13.
43. Cao J, Yu Z, Liu W, et al. Probiotic characteristics of *Bacillus coagulans* and associated implications for human health and diseases. *Journal of Functional Foods* 2020; 64: 103643.
44. Jain A, Li XH, Chen WN. Similarities and differences in gut microbiome composition correlate with dietary patterns of Indian and Chinese adults. *AMB Expr* 2018; 8: 104.
45. Gupta A, Dhakan DB, Maji A, et al. Association of *Flavonifractor plautii*, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India. *mSystems*; 4: e00438-19.
46. Ryan FJ, Ahern AM, Fitzgerald RS, et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat Commun* 2020; 11: 1512.
47. Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol* 2017; 14: 573–584.
48. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nat Commun* 2015; 6: 6528.
49. Flint HJ, Scott KP, Duncan SH, et al. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* 2012; 3: 289–306.
50. Becker C, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel Disease. *ILAR J* 2015; 56: 192–204.

51. Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. *J Clin Microbiol* 2014; 52: 398–406.
52. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* 2011; 60: 631–637.
53. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 2008; 105: 16731–16736.
54. Nemoto H, Kataoka K, Ishikawa H, et al. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. *Dig Dis Sci* 2012; 57: 2955–2964.
55. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe* 2014; 15: 382–392.
56. Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat Microbiol* 2018; 3: 337–346.
57. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. *Nature* 2011; 473: 174–180.
58. Bennet SMP, Polster A, Törnblom H, et al. Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. *Am J Gastroenterol* 2016; 111: 1165–1176.
59. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol* 2006; 4: 754–759.
60. Mitsuyama K, Tomiyasu N, Takaki K, et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. *Mediators Inflamm* 2006; 2006: 26875.
61. Ma X, Yan W, Zheng H, et al. Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. *F1000Res* 2015; 4: F1000 Faculty Rev-1465.
62. Mavropoulou E, Mechie N-C, Knoop R, et al. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. *PLOS ONE* 2020; 15: e0233811.
63. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. *J Clin Gastroenterol* 1995; 20: 123–126.
64. Kuwabara T, Ishikawa F, Kondo M, et al. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators of Inflammation* 2017; 2017: e3908061.
65. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, et al. Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. *Cureus* 2017; 9: e1177.
66. Mao L, Kitani A, Strober W, et al. The Role of NLRP3 and IL-1 β in the Pathogenesis of Inflammatory Bowel Disease. *Front Immunol* 2018; 9: 2566.
67. Coccia M, Harrison OJ, Schiering C, et al. IL-1 β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. *J Exp Med* 2012; 209: 1595–1609.

843 68. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel
844 disease--enhanced production during active disease. *Gut* 1990; 31: 686–689.

845 69. Marcus MM, Jardemark K, Malmerfelt A, et al. Augmentation by escitalopram, but not
846 citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral,
847 biochemical, and electrophysiological evidence. *Synapse* 2012; 66: 277–290.

848 70. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate
849 ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical
850 treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol*
851 2010; 105: 2218–2227.

852 71. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of
853 inflammatory bowel diseases: A meta analysis and systematic review. *Journal of*
854 *Cellular Physiology* 2018; 233: 2091–2103.

855 72. Schlee M, Harder J, Köten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte
856 beta-defensin 2. *Clin Exp Immunol* 2008; 151: 528–535.

857 73. Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel
858 syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol* 2015;
859 21: 3072–3084.

860 74. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal
861 health and disease. *Nat Rev Gastroenterol Hepatol* 2010; 7: 503–514.

862 75. Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional
863 gastrointestinal disorders: a systematic review and meta-analysis. *Acta Paediatr* 2014;
864 103: 365–372.

865